AMG 335 Expanded Access Program for IgG4-Related Disease
- Registration Number
- NCT06590051
- Lead Sponsor
- Amgen
- Brief Summary
Expanded access requests for AMG 335 may be considered for adult patients with a confirmed diagnosis of IgG4-related disease. To request access, use Responsible Party contact information provided in this record.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- AVAILABLE
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Exclusion Criteria
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of AMG 335 are being explored for IgG4-related disease treatment?
How does AMG 335 compare to standard-of-care treatments for IgG4-related disease in clinical outcomes?
Which biomarkers are used to select IgG4-related disease patients for AMG 335 expanded access?
What adverse events have been reported with AMG 335 in IgG4-related disease trials and how are they managed?
Are there combination therapies or competitor drugs targeting IgG4-related disease alongside AMG 335?